CN114026072A - 治疗特发性肺纤维化的方法 - Google Patents

治疗特发性肺纤维化的方法 Download PDF

Info

Publication number
CN114026072A
CN114026072A CN202080045478.XA CN202080045478A CN114026072A CN 114026072 A CN114026072 A CN 114026072A CN 202080045478 A CN202080045478 A CN 202080045478A CN 114026072 A CN114026072 A CN 114026072A
Authority
CN
China
Prior art keywords
days
compound
group
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080045478.XA
Other languages
English (en)
Chinese (zh)
Inventor
赵焰平
王红军
姜媛媛
仲伟婷
赵静
李晶
刘伟娜
周丽莹
刘亚男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Priority to CN202510159677.8A priority Critical patent/CN119868365A/zh
Publication of CN114026072A publication Critical patent/CN114026072A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080045478.XA 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法 Pending CN114026072A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510159677.8A CN119868365A (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019092675 2019-06-25
CNPCT/CN2019/092675 2019-06-25
PCT/CN2020/097881 WO2020259528A1 (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510159677.8A Division CN119868365A (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法

Publications (1)

Publication Number Publication Date
CN114026072A true CN114026072A (zh) 2022-02-08

Family

ID=74061495

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080045478.XA Pending CN114026072A (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法
CN202510159677.8A Pending CN119868365A (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510159677.8A Pending CN119868365A (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法

Country Status (11)

Country Link
US (1) US12582653B2 (https=)
EP (1) EP3992183A4 (https=)
JP (1) JP7615061B2 (https=)
KR (1) KR20220029681A (https=)
CN (2) CN114026072A (https=)
AU (1) AU2020305979B2 (https=)
BR (1) BR112021026214A2 (https=)
CA (1) CA3144113A1 (https=)
IL (1) IL289192A (https=)
TW (1) TWI804743B (https=)
WO (1) WO2020259528A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539276A (ja) * 2020-08-31 2023-09-13 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ関連タンパク質キナーゼ阻害剤の塩、その固体形態、その調製方法およびその使用
CA3209240A1 (en) * 2021-02-22 2022-08-25 Samuel D. Waksal Rock2 inhibitor for the treatment of viral infection
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
TW202327608A (zh) * 2021-09-17 2023-07-16 北京泰德製藥股份有限公司 治療病毒感染的方法
IL311447A (en) * 2021-09-18 2024-05-01 Beijing Tide Pharmaceutical Co Ltd A solid form of a Rho-linked protein kinase inhibitor or a solvate thereof, a method of preparation and use thereof
KR20240095429A (ko) * 2021-11-16 2024-06-25 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rock2 억제제의 나노결정 제제 및 이의 제조방법
WO2023134688A1 (zh) * 2022-01-13 2023-07-20 武汉朗来科技发展有限公司 一种rock抑制剂的盐及盐的晶型、组合物和药物用途
EP4591863A1 (en) * 2022-10-13 2025-07-30 Beijing Tide Pharmaceutical Co., Ltd. Method for treating pneumoconiosis
WO2025017499A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
IL325831A (en) 2023-07-17 2026-03-01 Graviton Bioscience Bv ROCK2 inhibitor formulations for central nervous system disorders
WO2025069008A1 (en) 2023-09-28 2025-04-03 Graviton Bioscience Bv Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019001572A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138335A1 (en) * 2015-02-27 2016-09-01 Lycera Corporation Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
AR110401A1 (es) 2016-12-21 2019-03-27 Chiesi Farm Spa Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019001572A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陈临溪等: "《中国疾病信号通路与靶向治疗学》", vol. 1, 安徽科学技术出版社, pages: 174 *

Also Published As

Publication number Publication date
EP3992183A1 (en) 2022-05-04
US20220233538A1 (en) 2022-07-28
EP3992183A4 (en) 2023-06-21
TW202114679A (zh) 2021-04-16
KR20220029681A (ko) 2022-03-08
US12582653B2 (en) 2026-03-24
AU2020305979A1 (en) 2022-02-17
IL289192A (en) 2022-02-01
JP2022539329A (ja) 2022-09-08
JP7615061B2 (ja) 2025-01-16
AU2020305979B2 (en) 2026-04-23
WO2020259528A1 (zh) 2020-12-30
CA3144113A1 (en) 2020-12-30
CN119868365A (zh) 2025-04-25
TWI804743B (zh) 2023-06-11
BR112021026214A2 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
CN114026072A (zh) 治疗特发性肺纤维化的方法
US7928119B2 (en) Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
EP3932404A1 (en) Method for treating fatty liver disease and/or steatohepatitis
WO2024078592A1 (zh) 靶向成纤维细胞活化蛋白的药物及其应用
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
JP7665529B2 (ja) ジアミノピリミジン化合物を使用することによって咳を治療する方法
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
HK40121343A (zh) 治疗特发性肺纤维化的方法
EP4591863A1 (en) Method for treating pneumoconiosis
WO2026026465A1 (zh) 酰胺取代的2-氧代吡啶类化合物的用途
JP2025539347A (ja) Ｋｒａｓ阻害剤とｓｈｐ２阻害剤とを含む併用療法
HK40063168A (en) Method for treating cough by using diaminopyrimidine compound
JP2025529076A (ja) ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis
HK40054971A (en) Method for treating fatty liver disease and/or steatohepatitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063173

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination